Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Isis Pharmaceuticals begins phase II study of ISIS-FXIRx in end-stage renal disease

Nov. 3, 2015

Taiho starts phase I trial of TAS-303 in women with stress urinary incontinence

Nov. 3, 2015

Revive Therapeutics' bucillamine receives orphan drug designation for cystinuria

Oct. 30, 2015

Researchers devise mouse model of nocturnal polyuria

Oct. 26, 2015

AF-219 improves symptoms in patients with interstitial cystitis/bladder pain syndrome

Oct. 26, 2015

Cinryze receives FDA fast track designation

Oct. 14, 2015

Astellas Pharma describes prostanoid EP4 antagonists

Oct. 14, 2015

New financing round at Pharmalink to fund development of phase III program for Nefecon

Oct. 6, 2015

Fexeric approved in Europe for hyperphosphatemia in patients with chronic kidney disease

Sep. 25, 2015

NecroX-7 reduces renal ischemia-reperfusion injury in vivo

Sep. 17, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...